nab-paclitaxel, carboplatin, and bemotuzumab
PreclinicalMonoclonal antibody
nab-paclitaxel, carboplatin, and bemotuzumab is one of 40 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
249 competitors in Triple-Negative Breast Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Halaven
EisaiPhase 3
Paraplatin
AAvyxa
Phase 3
Gemzar
Johnson & JohnsonPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Halaven
EisaiPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Xtandi
AstellasPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details